Objectives: The aims of the study were to determine whether mild, occult sleep-disordered breathing (SDB) moderates the efficacy of cognitive behavioral therapy for insomnia (CBTI) in older adults and to explore whether CBTI reduces the number of patients eligible for positive airway pressure (PAP) therapy.
INTRODUCTION
A pproximately one third of community-dwelling older adults have symptoms of insomnia (1), a condition associated with increased healthcare costs and mortality. A wide body of evidence demonstrates that cognitive behavioral therapy for insomnia (CBTI) reduces sleep disturbance among older patients with insomnia (2) (3) (4) . Efforts are underway to expand CBTI training among mental health providers, and several research studies show that CBTI can be delivered over the telephone and in condensed formats (e.g., Brief behavioral treatment for insomnia [BBTI] ) (2, 5, 6) . These efforts are providing increased opportunities for patients to access CBTI, which may in turn lead to reductions in sleep disturbance among older adults.
Nearly one third of older adults with insomnia also have undiagnosed sleep-disordered breathing (SDB), a condition that responds to therapies such as positive airway pressure (PAP) (7, 8) . The optimal treatment sequence (concurrent versus sequential SDB treatment and CBTI) for improving sleep disturbance among patients with insomnia and comorbid SDB has only been examined in a limited number of studies, which report inconsistent findings (2, 9, 10) . One prospective randomized crossover study reported that treating SDB first yielded more improvement in insomnia symptoms than starting with CBTI, suggesting that treating SDB first may be the optimal approach when tackling insomnia complaints among patients with co-occurring insomnia and SDB (10) . Another study tested sequential CBTI and SDB therapy in a middle-aged nonveteran population with refractory insomnia and found that fewer than half of participants reached a nonclinical insomnia level after CBTI, whereas 88% achieved this end point after adding SDB therapy (9) . However, subgroup analyses from a third study, whose primary finding was that BBTI conducted in an older nonveteran population is associated with remission of insomnia (55% intervention versus 13% control), found no differential effects of BBTI associated with SDB status (2) . Several other CBTI trials have excluded older adults with SDB symptoms or SDB diagnoses (11) (12) (13) (14) (15) (16) .
There are a few scenarios in which a provider might want to begin CBTI before initiating SDB treatment. In some instances, insomnia may be the patient's only indication for treating mild SDB (i.e., the patient may lack excessive daytime sleepiness, impaired cognition, mood disorders, hypertension, ischemic heart disease, or history of stroke, which are other indications for PAP therapy according to the Centers for Medicare and Medicaid Services [CMS] (17)), and therefore, a trial of CBTI may be warranted to see whether insomnia symptoms resolve without SDB therapies such as PAP. Secondly, many patients with psychophysiologic insomnia have difficulty falling asleep at the beginning of the night or falling back asleep after awakening from stimuli (18) , which could be exacerbated by stimuli such as noise from a leaking PAP mask and/or tactile stimulation from PAP headgear or tethered PAP tubing. Increased length of nighttime awakenings could reduce acceptance of PAP, and because CBTI decreases the length of nighttime awakenings, this could improve adherence to SDB therapies. Finally, there may be delays in accessing SDB therapy because of delays in insurance approvals, crowded appointment schedules at durable medical equipment companies, intermittent interruptions in the supply of PAP units, or difficulty paying out-of-pocket costs associated with SDB therapies (19) .
In the context of a larger randomized controlled trial testing CBTI delivered by a supervised sleep coach compared with a sleep education control condition (20) , the primary aim of the current study was to determine whether CBTI results differ on the basis of SDB status. We hypothesized that at 6-month follow-up, the presence of untreated mild SDB would not limit the improvements in sleep efficiency (SE), sleep onset latency (SOL), wake after sleep onset (WASO), total wake time (TWT), or Pittsburgh Sleep Quality Index (PSQI) total score among older adults randomized to CBTI versus a sleep education control condition. We also hypothesized that CBTI would decrease the number of patients with mild SDB who meet CMS indications for SDB therapy.
METHODS Overview
Baseline, posttreatment, and 6-and 12-month follow-up data for a subset of individuals enrolled in a randomized controlled trial testing a novel delivery model for CBTI (i.e., CBTI provided by a health educator supervised by a sleep psychologist) among older veterans were included for this analysis (20) . For the current analyses, we selected the subgroup of participants with an apnea-hypopnea index (AHI) of less than 15 (mild SDB [AHI ≥5 to <15] or no SDB [AHI <5]), to align with the CMS criteria for mild and no SDB (N = 134) (17) .
Procedures
Participants for the trial were identified through a multistage screening process that involved a postal survey, telephone interview, face-to-face interview, home sleep study, and medical chart review. Details of the postal survey and the trial have been reported previously (20, 21) . Through this screening process, we identified veterans who met the following criteria: 60 years or older, presence of a chronic insomnia disorder (International Classification of Sleep Disorders-2 [ICSD-2] criteria), no known history of sleep apnea (by patient report), Mini-mental State Examination (MMSE) score of 24 or greater, healthcare visit at our Department of Veteran Affairs (VA) between August 2009 and June 2011, no serious physical or mental health issues that would preclude participation in the trial, and AHI of less than 20 (as described previously, only patients with AHI < 15 were included in the current analyses). Eligible patients were randomized to one of following three groups: individual CBTI, group CBTI, or a sleep education control condition. CBTI included sleep restriction, stimulus control, and cognitive therapy and was provided by health educators with weekly telephone supervision by a sleep psychologist (17) . Controls received general information about sleep. Both the CBTI and control conditions involved five sessions for 6 weeks. Assessments were performed at baseline, posttreatment, and at 6-and 12-month follow-up. Twelve-month follow-up data were collected to assess maintenance of outcomes. Our predefined primary end points were collected at the 6-month follow-up visit.
Instruments

Unattended In-home Sleep Study
At baseline, participants underwent a single-night, unattended in-home sleep study (WatchPAT, WP100, Itamar Medical). After we visually inspected the recording, the AHI was calculated using the manufacturer's automated, validated scoring algorithms (22) . We grouped patients into two groups: no SDB (AHI 0 to <5) and mild SDB (AHI ≥ 5 to < 15).
Sleep Diaries
At each assessment time point, participants kept a sleep diary that included self-reported daily bedtime and rise times, SOL, and number of nighttime awakenings. We then computed the mean nighttime total sleep time, WASO, TWT at night, and SE.
Actigraphy
At each assessment time point, participants wore a wrist actigraph (Actiwatch Spectrum, Philips Respironics) on their dominant arm for 7 consecutive days and nights. Research staff visually inspected the raw actigraphy data (1-minute epoch) to identify artifacts and then scored the recordings. Sleep diaries were used to determine nighttime and daytime periods for scoring and analysis of actigraphy data. We calculated actigraphically measured SE (23) .
Other Clinical and Demographic Variables
We collected information on patients' race/ethnicity, educational level, employment status, and marital status. The VA's Austin Automation Center administrative database provided each participant's sex and date of birth, which enabled us to calculate age. At baseline only, participants were asked through a structured interview whether they had a history of hypertension, a history of stroke, or a history of a heart attack. At each assessment time point (including baseline), participants completed the PSQI (total possible score = 0-21; scores > 5 suggest significant sleep disturbance) (24), Insomnia Severity Index (ISI = 0-28; scores ≥ 15 suggest clinical insomnia) (25), the Epworth Sleepiness Scale (ESS = 0-24; scores ≥ 10 suggest excessive daytime sleepiness) (26) , and the Patient Health Questionnaire-9 (PHQ-9 = 0-27; scores ≥ 5 are suggestive of depression) (27) . At each assessment time point, we also determined whether the participant met ICSD-2 criteria for insomnia, by analyzing the participants' responses to assessment items (collected through structured interview during the scheduled assessment periods) that were specifically designed by our research team to determine whether the participant met the ICSD-2 General Criteria for Insomnia.
Our predefined primary outcomes were SOL, WASO, TWT, SE (sleep diary and actigraphy), and total PSQI score collected at the 6-month follow-up.
Ethics
All study procedures and materials were approved by VA Greater Los Angeles Healthcare System Institutional Review Board. All participants provided written informed consent.
Statistics
Descriptive statistics (e.g., mean, standard deviations) were calculated to characterize the sample. Demographic characteristics were compared for participants on the basis of SDB status (AHI < 5 versus AHI ≥ 5) using t tests for continuous variables and Fisher exact tests for categorical variables.
A repeated-measures analysis of variance (ANOVA) model that included an interaction term (SDB status * assigned treatment arm) compared sleep outcomes (between CBTI and controls for patients with versus without mild SDB) at baseline, posttreatment, 6-month follow-up, and 12-month follow-up. Using the interaction term in this model, we compared differences in treatment effects for patients with mild SDB versus without mild SDB (28) . For the six primary (a priori) outcomes, we used a Bonferroni-adjusted α level of .0083 (0.05/6). For the secondary outcomes (posttreatment and 12-month follow-up outcomes), we used an α level of .01.
To provide a visual representation of our analyses, we used the means and standard error of the mean generated from the repeated-measures ANOVA models to depict the sleep measures as a function of treatment group assignment and SDB status over time (Fig. 1) .
We calculated Pearson product-moment correlation coefficients to measure the strength of association between AHI and baseline sleep measures and between AHI and the change in sleep measures from baseline to 6-month follow-up for the CBTI-I and controls.
Finally, to assess for changes in the number of patients with indications for PAP therapy at our predefined primary end point (6-month follow-up), we identified the following two groups of patients at baseline: (1) patients with an AHI of 5 or greater, an ICSD-2 diagnosis of insomnia, and no other indication for PAP therapy at baseline and (2) patients with AHI of 5 or greater, an ICSD-2 diagnosis of insomnia, and at least one other indication for PAP therapy at baseline. We operationalized "no other indications for FIGURE 1. Sleep measure means and standard error of the mean, by time (1 = baseline; 2 = posttreatment; 3 = 6-month follow-up; 4 = 12-month follow-up), SDB status (normal, mild), and treatment group assignment (dashed line = cognitive behavioral therapy for insomnia; solid line = sleep education control). SOL = sleep onset latency; WASO = wake after sleep onset; TWT = total wake time; SE = sleep efficiency; PSQI = Pittsburgh Sleep Quality Index.
PAP therapy" (on the basis of CMS criteria) in the following manner: at baseline, the patient denied history of stroke, heart attack, or hypertension and had a PHQ-9 of less than 10, ESS of less than 10, and MMSE of 24 or greater (MMSE < 24 was an exclusion criterion). To measure the reduction in participants meeting CMS indications for PAP therapy, we calculated the number of patients in group 1 who no longer met ICSD-2 criteria for insomnia at 6-month follow-up. To examine whether CBTI reduces the number of participants meeting CMS indications for PAP therapy, we used Fisher exact test to examine associations between trial arm assignment and presence of insomnia at 6-month follow-up for group 1. Because CBTI could have worsened ESS and PHQ-9 scores (possibly making participants eligible for PAP therapy on the basis of excessive daytime sleepiness or a mood disorder), we also cross-tabulated the proportion of patients who had an ESS of 10 or greater at 6-month follow-up and no other indication for PAP therapy among the patients randomized to CBTI. We repeated this for a PHQ-9 of 10 or greater.
RESULTS
Baseline
Pretreatment demographic and clinical variables by SDB status are summarized in Table 1 . The sample was composed primarily of non-Hispanic white males. No significant differences in age, sex, educational level, race/ethnicity, or marital status were observed between participants with an AHI < 5 (no SBD) versus 5 ≥ AHI < 15 (mild SDB). Seventy-one percent (n = 95) of the analyzed sample had an AHI of 5 or greater (and < 15) suggesting mild SDB. Sleep assessments at baseline are summarized in Table 2 .
Primary End Points (6-Month Follow-up) Table 3 (column A) provides the CBTI and sleep education control groups' outcomes for participants with and without SDB. As compared with participants with mild SDB who received sleep education, participants with mild SDB who received CBTI had significant improvements in SOL (p = .0078) and PSQI total score (p = .002), but they did not have significant improvements in WASO (p = .1), TWT (p = .02), diary-measured SE (p = .01), or actigraphically measured SE (p = .7). The test of the interaction between SDB status and assigned treatment arm resulted in no statistically significant differences in treatment effect associated with CBTI for participants without and with mild SDB.
Centers for Medicare and Medicaid Services Indications for PAP Therapy
At baseline, 95 participants had mild SDB, 24 of whom had insomnia as their only other indication for PAP therapy. At the 6-month follow-up, insomnia status data were available for 20 participants with mild SDB (14 CBTI, 6 sleep education control), and of these participants, six (45%) no longer met CMS indications for PAP therapy (6 CBTI [42.9%] versus 3 sleep education control [50.0%], Fisher exact p > .99). Of the nine mild SDB participants without insomnia at the 6-month follow-up, none developed an ESS of 10 or greater or a PHQ-9 of 10 or greater.
Secondary End Points
In Tables 4 and 5 , we present results from the posttreatment assessments and 12-month assessments, respectively. We found no statistically significant differences in treatment effect associated with CBTI for participants without and with SDB at posttreatment and 12 months, where a p value of less than .01 was considered statistically significant (α = .01).
Correlations between baseline AHI and baseline sleep measures and between AHI and the change in sleep measures from baseline to 6-month follow-up are presented as supplemental material (http://links.lww.com/PSYMED/ A284). Baseline AHI was not significantly correlated with any of the baseline sleep measures or with the change in sleep measures for either the CBTI or control groups. As expected, diary-measured SE and TWT, which are both commonly reported in insomnia trials, were highly correlated at baseline (r = −.96), and changes in SE (from sleep diary) and changes in TWT from baseline to 6-month follow-up were highly correlated for the CBTI group (r = −.95) and control group (r = −.98).
DISCUSSION
In this study, we examined whether the presence of mild, occult SDB limits the efficacy of CBTI. We found that participants with mild SDB reported substantial reductions in SOL and improvements in sleep quality associated with CBTI and that the effect of CBTI is similar for older veterans with and without untreated mild SDB. We also found that for 24 mild SDB participants (15.4%), insomnia was their only CMS indication for PAP therapy at baseline, and of the mild SDB participants followed-up at 6 months, 45% no longer met CMS indications for PAP therapy.
Few other studies have analyzed whether CBTI is efficacious in patients with mild, occult SDB, and none have specifically studied older veterans, a group that may have increased opportunity to receive behavioral treatments for their sleep disturbance due to efforts to expand access to CBTI (10,29). Our results suggest that patients with insomnia and mild, occult SDB are likely to see improvements in their sleep when they are treated with CBTI, with reductions in TWT, improved SE, and better sleep quality. Although our study was not designed to test acceptance or adherence to PAP therapy, the improvements in sleep quality have the potential to reduce awakenings associated with stimuli from SDB therapies such as PAP-related noise. Our findings are similar to those reported by Buysse et al. (2) , who found that nonveterans with SDB did not have different BBTI results than those without SDB. However, our study differs in that our participants underwent CBTI, not BBTI, and our intervention was provided by health educators who were supervised by a sleep psychologist during the delivery of the intervention.
Our findings may also have implications for treating older veterans with mild, occult SDB that occurs in the context of insomnia. Currently, CMS pays for PAP therapy if patients with mild sleep apnea have another indication for therapy such as insomnia, excessive daytime sleepiness, impaired cognition, mood disorder, hypertension, ischemic heart disease, or history of stroke (17) . A large percentage of the mild SDB patients in our study for whom insomnia was their only CMS indication for PAP therapy no longer had another indication for PAP therapy at 6-month follow-up. We did not find that CBTI was significantly associated with a larger reduction in the number of mild SDB patients meeting CMS criteria PAP therapy, but this result may have been due to insufficient power to detect a difference. Given the high rates of nonadherence associated with PAP therapy and the long-term costs associated with PAP equipment replacement and maintenance, an attractive alternative for mild SDB patients and their payers may be to first address the patient's insomnia when there are no other indications for a PAP prescription.
Limitations of our study include our population, which was primarily composed of non-Hispanic males. In addition, we used unattended, in-home sleep study to measure participants' AHI, which may have resulted in incorrectly categorizing patients as having mild SDB (or as normal). However, unattended, in-home sleep studies are increasingly used in routine clinical practice to make determinations of patients' SDB status and severity. We were unable to assess differences in dichotomous treatment remission and dichotomous treatment response outcomes because of limited sample size. Another limitation is that the number of participants for whom insomnia was their only other indication for PAP therapy was small, because of high rates of comorbid conditions in older adults (particularly older veterans) such as hypertension, which is another indication for PAP therapy in patients with mild SDB.
The current study provides support for employing CBTI in older adults with mild, occult SDB to improve sleep outcomes and further suggests that a subset of older adults with mild, occult SDB might no longer meet CMS indications .002* −0.1 (−3.1 to 2.8)
.93 AHI = apnea-hypopnea index; SDB = sleep-disordered breathing; CI = confidence interval; CBTI = cognitive behavioral therapy for insomnia; SOL = sleep onset latency; WASO = wake after sleep onset; TWT = total wake time; SE = sleep efficiency; PSQI = Pittsburgh Sleep Quality Index. For statistical analysis, repeated-measures ANOVA was used. for PAP therapy after successful CBTI. The effect of CBTI on AHI in patients with mild, occult SDB should be studied. Additional studies with larger sample sizes are needed to identify the success rate of CBTI for improving sleep disturbance among patients with mild, occult SDB and no other indications for PAP therapy.
